CMS implements Inflation Reduction Act payment increase for qualifying biosimilars
Effective Oct. 1 for five years, the Centers for Medicare & Medicaid Services will pay Average Sales Price plus 8%, rather than ASP plus 6%, for biosimilars whose average sales price does not exceed the price of the reference biological product. The payment increase was included in the Inflation Reduction Act of 2022. For new biosimilars that qualify, the five-year period will begin on the first day of the calendar quarter for which ASP payment for that biosimilar begins under Medicare Part B.
Related News Articles
Headline
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted…
Headline
The Centers for Medicare & Medicaid Services March 31 released a request for applications for its new accountable care organization model, the Long-term…
Headline
The U.S. Court of Appeals for the 4th Circuit March 31 upheld a preliminary injunction issued by the U.S. District Court for the District of West Virginia…
Headline
The Centers for Medicare & Medicaid Services Innovation Center yesterday announced the launch of a new model under Medicaid and the Children’s Health…
Perspective
A hospital patient from the 1990s would likely marvel at the pace of progress in health care just a generation later. America’s hospitals and health systems…
Headline
The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect…